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Abstract: 
 
Prostate cancer (PCA) is the second most malignancy in American men. Advanced stage PCA 
cells possess unlimited replication potential as well as resistance to apoptosis. Therefore, 
targeting survival mechanisms and activating apoptotic machinery in PCA cells using nontoxic 
phytochemicals is suggested as an attractive strategy against this deadly malignancy. In the 
present study, we assessed the effect of one such botanical agent, namely isosilybin A, on 
apoptotic machinery and key members of cell survival signaling [Akt, NF‐κB, and androgen 
receptor (AR)] in different PCA cells. Results showed that isosilybin A (90–180 µM) treatment 
significantly induces apoptotic death by activating both extrinsic (increased level of DR5 and 
cleaved caspase 8) and intrinsic pathways (caspase 9 and 3 activation) of apoptosis in three 
different human PCA cell lines namely 22Rv1, LAPC4, and LNCaP. Further, isosilybin A 
treatment decreased the levels of phospho‐Akt (serine‐473), total Akt, and the nuclear levels of 
NF‐κB constituents (p50 and p65). Isosilybin A treatment also decreased the AR and PSA level 
in 22Rv1, LAPC4, and LNCaP cells. Employing pan‐caspase inhibitor (Z‐VAD.fmk), we 
confirmed that isosilybin A‐mediated decreased AR is independent of caspases activation. 
Temporal kinetics analysis showed that the primary effect of isosilybin A is on AR, as decrease 
in AR was evident much earlier (4 h) relative to caspase activation and apoptosis induction 
(12 h). Overall, our results demonstrated that isosilybin A activates apoptotic machinery in PCA 
cells via targeting Akt–NF‐κB–AR axis; thereby, indicating a promising role for this 
phytochemical in the management of clinical PCA. 
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Article: 
 
INTRODUCTION 
 
Prostate cancer (PCA) is the most commonly diagnosed noncutaneous neoplasm and is the 
second leading cause of cancer‐related deaths in American men after lung cancer [1]. According 
to the American Cancer Society, about 192 280 cases and 27 360 deaths due to PCA were 
estimated in American men in 2009 [1]. The currently available therapies such as radiotherapy, 
chemotherapy, and hormonal therapy seem inadequate and noneffective towards advanced stage 
PCA cells, and toxic towards normal tissues of the body; therefore, alternative measures are 
warranted for the better management of PCA. Prevention and therapeutic intervention by 
phytochemicals is an attractive alternative, as their efficacy, human acceptance, and nontoxicity 
is supported by epidemiological and experimental evidences [2-4]. In this regard, the cancer 
chemopreventive and therapeutic role of silymarin (isolated from the seeds of milk 
thistle, Silybum marianum) has been extensively reported against various cancers including PCA 
[5, 6]. 
 
Silymarin is a mixture of various polyphenols, consisting of seven distinct flavonolignans, 
namely silybin A, silybin B, isosilybin A, isosilybin B, silydianin, silychristin, isosilychristin, 
and one flavonoid taxifolin [7-9]. In recent studies, we compared the biological effect of these 
pure compounds on various antiproliferative end points, including PCA cell growth suppression, 
cell‐cycle distribution, clonogenic potential, inhibition of androgen receptor (AR) signaling, and 
DNA topoisomerase IIα promoter activity [8, 10-12]. In these studies, isosilybin A was identified 
as one of the biologically active constituents of silymarin with strong propensity to induce cell 
death in PCA cells [10, 13]. 
 
Cell survival is maintained by a delicate balance between antiapoptotic and proapoptotic stimuli. 
Dysregulation of this balance could disrupt the equilibrium between cell proliferation and cell 
death, and it is considered an essential event in the development and progression of cancer [14]. 
In general, apoptosis is activated through two major signaling pathways, namely the intrinsic and 
extrinsic pathways [15-18]. The intrinsic apoptotic pathway is triggered in response to DNA 
damage or other types of severe cell stress and involves the release of cytochrome c from the 
intermembrane space of the mitochondria [15-18]. The released cytochrome c interacts with 
APAF1 (apoptotic protease‐activating factor 1) and forms an “apoptosome” that activates 
caspase 9, leading to the activation of downstream caspases (3, 6, and 7) and the apoptotic death 
response [15-18]. The extrinsic pathway of apoptosis is triggered in response to proapoptotic 
ligands [tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL), tumor necrosis factor 
(TNF), Fas ligands, etc.], which bind and activate specific proapoptotic death receptors [DRs; 
DR4, DR5, TNF receptor (TNFR), Fas, etc.] [17, 18]. Ligand‐induced activation of DRs leads to 
the recruitment of the adaptor Fas‐associated death domain (FADD) and activation of protease 
caspases 8 [15, 17, 18]. Caspase 8 cleaves and activates caspase 3 as well as other downstream 
caspases, thereby triggering apoptosis [15, 17, 18]. Cancer cells with alterations in the molecules 
involved in the above‐mentioned cell death signaling are often resistant to radio‐ and 
chemotherapy that acts primarily through induction of apoptosis [16-18]. Therefore, activating 
apoptotic machinery in cancer cells using nontoxic phytochemicals could be an effective 
measure in PCA management. Phytochemical treatments could cause apoptotic death either by 
engagement of DRs or by stimulation of intrinsic pathway in cancer cells. 
 
Recent studies have demonstrated that protein kinase B (Akt), nuclear factor kappa B cells (NF‐
κB), and AR‐based signaling are the key regulators of cellular survival and apoptotic machinery; 
and uncontrolled activity of these signaling molecules is critical for the growth and progression 
of PCA [15, 19-21]. Together, this axis constitutes a potential therapeutic target for the treatment 
of PCA. Therefore, in the present study, we analyzed the mechanistic details underlying the 
proapoptotic effect of isosilybin A and also analyzed its effect on the Akt, NF‐κB, and AR 
signaling. Our results suggest that isosilybin A treatment activates apoptotic pathways in PCA 
cells via targeting the Akt–NF‐κB–AR axis. 
 
MATERIALS AND METHODS 
 
Reagents 
 
Isosilybin A was isolated (purity >97%) from powdered extract (1 kg; lot 37501) of the fruits 
of Silybum marianum (L.) Gaertn. (obtained from Euromed, S.A., Barcelona, Spain, a part of the 
Madaus Group, Köln, Germany) as described in detail previously [22]. Antibodies for cleaved 
poly(ADP‐ribose) polymerase (cPARP), cleaved caspase 3, cleaved caspase 8, cleaved caspase 
9, phospho‐Akt (serine‐473), total Akt, phospho‐Bcl2 (serine‐70), total Bcl2, BAD, BAX, BID, 
SMAC/DIABLO, and antirabbit peroxidase‐conjugated secondary antibody were obtained from 
Cell Signaling (Beverly, MA). Antibodies for DR5, p65, p50, and AR were from Santa Cruz 
Biotechnology (Santa Cruz, CA). Prostate‐specific antigen (PSA) antibody was from Dako A/S 
(Glostrup, Denmark) and antibody for β‐actin was from Sigma–Aldrich Chemical Co. (St Louis, 
MO). α‐Tubulin antibody was from Neomarkers (Fremont, CA). ECL detection system and 
antimouse HRP‐conjugated secondary antibody were from GE Healthcare (Buckinghamshire, 
UK). RPMI1640 media, Iscoves's modified Dulbecco's minimal essential medium (IMDM), fetal 
bovine serum (FBS), and penicillin–streptomycin (P–S) (10 000 U/mL penicillin and 
10 000 µg/mL streptomycin) were from Invitrogen Corporation (Gaithersberg, MD). Bio‐Rad 
detergent‐compatible protein assay kit was from Bio‐Rad Laboratories (Hercules, CA). Pan‐
caspase inhibitor (Z‐VAD.fmk) was obtained from Enzyme System Products (Livermore, CA). 
All other reagents were obtained in their highest purity grade available commercially. 
 
Cell Culture 
 
Human PCA LNCaP and 22Rv1 cells were from the American Type Culture Collection 
(Manassas, VA). LAPC4 cells were kindly provided by Dr. Robert E. Reiter (UCLA, CA, USA). 
LNCaP and 22Rv1 cells were grown in RPMI‐1640 media supplemented with 10% FBS and 1% 
P–S at 37°C in a humidified 95% air and 5% CO2 atmosphere. LAPC4 cells were cultured in 
Iscoves's modified Dulbecco's medium with 15% FBS, and 1% P–S. Cells were treated with 
different concentrations (10–180 µM) of isosilybin A in dimethyl sulfoxide (DMSO) for desired 
durations, and total cell lysates or nuclear/cytoplasmic lysates were prepared as described 
earlier [23, 24]. An equal amount of DMSO (vehicle) was present in each treatment including 
control, which did not exceed 0.1% (v/v). Cells were also pretreated with Z‐VAD.fmk (50 µM 
for 2 h) followed by desired isosilybin A treatment. 
 
Apoptosis Assay 
 
Apoptosis assay was performed by the Hoechst assay as described previously [25]. Briefly, cells 
(22Rv1, LAPC4, or LNCaP) were plated to about 40–50% confluency and treated with isosilybin 
A (90–180 µM). At the end of each treatment time (24 or 48 h), both adherent and nonadherent 
cell populations were collected by brief trypsinization followed by washing with ice‐cold PBS. 
Cells were then stained with DNA binding dye Hoechst 33342 and PI, and the apoptotic 
population was quantified using a fluorescent microscope (Zeiss, Jena, Germany, Axioskop 2 
plus‐HBO 100) by counting cells/microscopic field (at 400×) in five fields in each triplicate 
sample. Apoptotic dead cells showed orange–red fluorescence (Hoechst‐stained), which was 
distinguished from necrotic cells showing bright red fluorescence (PI‐stained). 
 
Western Blotting 
 
For Western blotting, lysates (40–70 µg) were denatured in 2× SDS–PAGE sample buffer and 
were resolved on 8–16% Tris–glycine gels. The separated proteins were transferred to 
nitrocellulose membrane followed by blocking with 5% nonfat milk powder (w/v) in Tris‐
buffered saline (10 mM Tris–HCl, pH 7.5, 100 mM NaCl, 0.1% Tween‐20) for 1 h at room 
temperature. After blocking, the membranes were probed with desired primary antibodies for 2 h 
at room temperature and then overnight at 4°C followed by appropriate peroxidase‐conjugated 
secondary antibody for 1 h at room temperature and visualized by ECL detection system. In each 
case, blots were subjected to multiple exposures on the film to make sure that the band density is 
in the linear range. For all results autoradiograms/bands were scanned with Adobe Photoshop 6.0 
(Adobe Systems, Inc., San Jose, CA). To ensure equal protein loading, each membrane was 
stripped and reprobed with β‐actin antibody or α‐tubulin antibody. 
 
Statistics 
 
Statistical analyses were performed using SigmaStat 2.03 software (Jandel Scientific, San Rafael, 
CA). Data were analyzed using one‐way analysis of variance (ANOVA) followed by 
Bonferroni t‐test, and a statistically significant difference was considered to be at P < 0.05. 
 
RESULTS 
 
Isosilybin A Treatment Induces Apoptotic Death in Human PCA Cells 
 
Our earlier study provided the preliminary evidence that isosilybin A treatment induces apoptotic 
death in PCA cells [13], but its detailed effect on apoptosis remained unknown. In the present 
study, we examined the detailed effect of isosilybin A on apoptosis and cell survival related 
signaling molecules in three different human PCA cell lines carrying functional AR namely 
22Rv1, LAPC4, and LNCaP. 
 
First, we analyzed the effect of isosilybin A treatment on the induction of apoptotic death in PCA 
cells by Hoechst/PI assay. As shown in Figure 1A, isosilybin A (90–180 µM) increased the 
apoptotic population by 3.1‐ to 4.6‐fold and 3.7‐ to 4.8‐fold after 24 and 48 h of treatment, 
respectively, in 22Rv1 cells. In LAPC4 cells, isosilybin A (90–180 µM) caused 3‐ to 5.2‐fold and 
4.1‐ to 5.6‐fold increase in apoptotic population after 24 and 48 h of treatment, respectively 
(Figure 1B). Similarly, in LNCaP cells, isosilybin A treatment (90–180 µM) increased the 
apoptotic population by 2.7‐ to 4.0‐fold and 3.1‐ to 4.9‐fold after 24 and 48 h of treatment, 
respectively (Figure 1C). These studies showed that isosilybin A treatment induces apoptosis in 
different PCA cell lines. 
 
 
Figure 1. Isosilybin A induces apoptosis in human PCA 22Rv1, LAPC4, and LNCaP cells. (A–C) 22Rv1, LAPC4, 
and LNCaP cells were treated at 40–50% confluency with DMSO or isosilybin A (90, 135, and 180 µM) for 24 and 
48 h. At each treatment time, both adherent and nonadherent cell populations were collected and stained with DNA 
binding dyes Hoechst 33342/PI and analyzed for apoptotic population as detailed in the Materials and Methods 
Section. The quantified apoptosis data are presented as “fold change” and each bar represents mean ± standard error 
of mean of three samples. *P ≤ 0.001; Iso A, isosilybin A. 
 
Isosilybin A Treatment Activates Extrinsic and Intrinsic Pathways of Apoptosis 
 
Next, we examined the effect of isosilybin A on various molecules involved in extrinsic and 
intrinsic pathways of apoptosis in above‐mentioned human PCA cells. Our results showed that 
isosilybin A treatment (90 and 180 µM) activates both extrinsic and intrinsic pathways of 
apoptosis in 22Rv1, LAPC4, and LNCaP PCA cells. In 22Rv1 cells, isosilybin A treatment for 
24 and 48 h resulted in a strong increase in the level of cPARP, a known downstream substrate of 
caspase 3 and a well‐known marker for apoptosis (Figure 2A). The increase in cPARP was 
associated with increased levels of DR5 and cleaved caspase 8 as well as increased levels of 
cleaved caspases 9 and 3 (Figure 2A). In 22Rv1 cells, isosilybin A treatment also decreased the 
phosphorylation of Bcl2 at the serine‐70 site along with a slight decrease in the total level of 
Bcl2; however, it did not significantly affect the levels of BAD, BAX, cleaved BID, or 
SMAC/DIABLO under similar treatment conditions (data not shown). Similar to results in 
22Rv1 cells, isosilybin A treatment increased the level of cPARP, DR5, cleaved caspase 8, 
cleaved caspases 9 and 3 in LAPC4 and LNCaP cells (Figure 2B and C). We also examined the 
effect of a range of isosilybin A concentrations (10–180 µM) on cPARP and cleaved caspase 3 
revealing that the effect of isosilybin A on these molecules is concentration‐dependent 
(Figure 2D). Membranes were stripped and reprobed with α‐tubulin antibody to confirm equal 
protein loading. As the aforementioned results showed a strong activation of apoptotic 
machinery by isosilybin A, we next examined the effect of isosilybin A on key signaling 
molecules (Akt, NF‐κB, and AR), which are known to directly or indirectly regulate apoptosis in 
PCA cells [15, 19-21]. 
 
 
Figure 2. Effect of isosilybin A on various members of apoptotic machinery in human PCA 22Rv1, LAPC4, and 
LNCaP cells. (A–C) 22Rv1, LAPC4, and LNCaP cells were treated at 40–50% confluency with DMSO or isosilybin 
A (90 and 180 µM) for 24 and 48 h. At each treatment time, both adherent and nonadherent cells were harvested and 
cell lysates were prepared in nondenaturing lysis buffer. For each sample, 60–75 µg of protein lysate was used for 
SDS–PAGE and Western immunoblotting, and membranes were probed for cleaved PARP, DR5, cleaved caspase 8, 
cleaved caspase 9, cleaved caspase 3, phosphorylated, and total Bcl2. (D) LNCaP cells were treated with DMSO or 
isosilybin A (10–180 µM) for 48 h and total cell lysates were analyzed for cPARP and cleaved caspase 3 by Western 
blotting. Membranes were also stripped and reprobed with antitubulin antibody to confirm equal protein loading. 
 
Isosilybin A Treatment Decreases Phospho‐ and Total‐Akt in PCA Cells 
 
Akt is a serine/threonine kinase that plays an important role in cell survival and inhibition of 
apoptosis [15, 21]. The increased expression of Akt, either phosphorylated or nonphosphorylated 
form, has been associated with high Gleason scores as well as poor prognosis in PCA [26-28]. 
Our results showed that isosilybin A treatment reduces Akt phosphorylation at the serine‐473 
site, which was more pronounced in LNCaP and LAPC4 cells compared to 22Rv1 cells 
(Figure 3A–C). The decrease in Akt phosphorylation by isosilybin A was accompanied with 
reduced total levels of Akt (Figure 3A–C). Our results also showed that even the 10 µM dose of 
isosilybin A was effective in decreasing the phosphorylation of Akt in LNCaP cells (Figure 3D). 
In all cases, membranes were stripped and reprobed with β‐actin antibody to confirm equal 
protein loading. 
 
 
Figure 3. Effect of isosilybin A on phospho‐ and total‐Akt levels in human PCA 22Rv1, LAPC4, and LNCaP cells. 
(A–C) 22Rv1, LAPC4, and LNCaP cells were treated at 40–50% confluency with DMSO or isosilybin A (90 and 
180 µM) for 24 and 48 h. At each treatment time, both adherent and nonadherent cells were harvested and cell 
lysates were prepared in nondenaturing lysis buffer. For each sample, 50–70 µg of protein lysate was used for SDS–
PAGE and Western immunoblotting, and membranes were probed for phospho‐Akt serine‐473 and total Akt. (D) 
LNCaP cells were treated at 40–50% confluency with DMSO or isosilybin A (10–180 µM) for 48 h and total cell 
lysates were analyzed for phospho‐Akt serine‐473 and total Akt by Western blotting. In each case, protein loading 
was checked by stripping and re‐probing the membranes with β‐actin antibody. 
 
Isosilybin A Treatment Decreases Nuclear Levels of p50 and p65 
 
NF‐κB is a transcription factor that regulates the expression of genes involved in cell 
proliferation, antiapoptosis, angiogenesis, invasion, and metastasis of PCA cells [29-31]. In 
normal cells, NF‐κB is localized in the cytoplasm as an inactive complex bound by inhibitors 
known as inhibitor of kappa B (IκBs). Various signals can lead to phosphorylation and 
degradation of IκBs with the resultant translocation of active NF‐κB into the nucleus, where it 
binds to specific DNA sites and regulates gene expression. Next, we examined the effect of 
isosilybin A treatment on two important members of the NF‐κB family (p50 and p65). Results 
showed that isosilybin A treatment decreases the level of p50 and p65 in the nuclear fraction of 
22Rv1, LAPC4, and LNCaP cells after 24 and 48 h of treatment (Figure 4A–C). The effect of 
isosilybin A was more pronounced on p50 levels compared to that of p65, and was prominent 
mainly at the 180 µM concentration (Figure 4A–C). Under similar treatment conditions, 
isosilybin A had no significant effect on the levels of p50 and p65 in the cytoplasmic fractions 
(Figure 4A–C). Purity of nuclear and cytoplasmic fractions was confirmed by re‐probing 
membranes with histone H1 and tubulin, detectable only in nuclear and cytoplasmic fractions, 
respectively. 
 
 
Figure 4. Effect of isosilybin A on p50 and p65 levels in the cytoplasmic and nuclear fractions of human PCA 
22Rv1, LAPC4, and LNCaP cells. (A–C) 22Rv1, LAPC4, and LNCaP cells were treated at 40–50% confluency with 
DMSO or isosilybin A (90 and 180 µM) for 24 and 48 h. At indicated treatment times, both adherent and 
nonadherent cells were harvested and nuclear/cytoplasmic fractions were prepared and Western blotting was carried 
out for p50 and p65. Purity of nuclear and cytoplasmic fractions was confirmed by re‐probing membranes with 
histone H1 and tubulin, detectable only in nuclear and cytoplasmic fractions, respectively. 
 
Isosilybin A Treatment Decreases AR and PSA Level in PCA Cells 
 
AR is a ligand‐dependent transcription factor whose activation is initiated by androgen binding 
and its subsequent translocation to the nucleus. There, it binds to the DNA as a homodimer on 
androgen‐responsive elements (AREs) within the regulatory regions of target genes and regulates 
transcription of AR target genes such as PSA [32-34]. PSA is a kallikrein‐like serine protease 
that serves as an important clinical biomarker to monitor diagnosis, treatment response, 
prognosis, and progression in PCA patients [35]. Next, we examined the effect of isosilybin A 
treatment on AR and PSA level in PCA cells, where it decreased the total AR level in 22Rv1, 
LAPC4, and LNCaP cells (Figure 5A–C). We also observed a strong decrease in the levels of 
PSA (both secreted as well as intracellular) in all the three PCA cell lines. Further, our results in 
LNCaP cells also showed that the inhibitory effect of isosilybin A treatment (10–180 µM) on 
PSA level was dose‐dependent (Figure 5D). In all cases, membranes were stripped and reprobed 
with β‐actin antibody to confirm equal protein loading. 
 
 
Figure 5. Effect of isosilybin A on AR and PSA levels in human PCA 22Rv1, LAPC4, and LNCaP cells. (A–C) 
22Rv1, LAPC4, and LNCaP cells were treated at 40–50% confluency with DMSO or isosilybin A (90 and 180 µM) 
for 24 and 48 h. At each treatment time, media were collected. Further, both adherent and nonadherent cells were 
harvested and cell lysates were prepared in nondenaturing lysis buffer. For each sample, 40–60 µg of protein lysate 
was used for SDS–PAGE and Western immunoblotting, and membranes were probed for AR and PSA (intracellular 
and secreted). (D) LNCaP cells were treated at 40–50% confluency with DMSO or isosilybin A (10–180 µM) for 
48 h. Thereafter, media and total cell lysates were analyzed for PSA by Western blotting. Protein loading was 
checked by stripping and re‐probing the membranes with β‐actin antibody. For secreted PSA, loading volume of 
media was normalized with respective protein values of the total cell lysates. 
 
Role of Caspases in Isosilybin A‐Mediated Decrease in the AR 
 
Next, we examined whether the isosilybin A‐mediated decrease in the AR was due to activation 
of caspases. To accomplish that we pretreated the 22Rv1, LNCaP, and LAPC4 cells with pan‐
caspase inhibitor (Z‐VAD.fmk) (50 µM for 2 h) followed by isosilybin A (180 µM) treatment for 
24 h, and then examined the levels of AR, cPARP, and caspases. Results showed that in the 
presence of pan‐caspase inhibitor, isosilybin A‐mediated AR decrease was largely compromised 
in 22Rv1 cells but had only marginal effect in LAPC4 and LNCaP cells (Figure 6A). To further 
delineate the primary target of isosilybin A, next, we treated 22Rv1 cells with isosilybin A 
(180 µM) and conducted a temporal kinetic analysis of AR, cPARP, and cleaved caspase 3. As 
shown in Figure 6B, isosilybin A treatment resulted in significant AR decreases starting at 4 h, 
while cPARP and caspase 3 activation were evident only after 12 h of isosilybin A treatment. 
These results are suggestive that the effect of isosilybin A on AR could be a primary event as 
these decreases were evident much earlier relative to caspase activation and apoptosis induction 
(Figure 6B). 
 
 
Figure 6. (A) Effect of isosilybin A‐mediated caspases activation on AR level in human PCA 22Rv1, LAPC4, and 
LNCaP cells. 22Rv1, LAPC4, and LNCaP cells were pretreated with pan‐caspase inhibitor Z‐VAD.fmk (50 µmol/L, 
2 h) and incubated with DMSO or isosilybin A (180 µM) for another 24 h. At the end of the treatment, both adherent 
and nonadherent cells were harvested and cell lysates were prepared in nondenaturing lysis buffer. For each sample, 
50–75 µg of protein lysate was used for SDS–PAGE and Western immunoblotting, and membranes were probed for 
AR, cPARP, cleaved caspase 9, and cleaved caspase 3. Protein loading was checked by stripping and re‐probing the 
membranes with tubulin antibody. (B) Temporal kinetic analysis of isosilybin A effect on AR, cPARP, and cleaved 
caspase 3. 22Rv1 cells were treated with DMSO or isosilybin A (180 µM) and cell lysates were prepared after 4, 8, 
12, 18, and 24 h of treatment. For each sample, 50–70 µg of protein lysate was used for SDS–PAGE and Western 
immunoblotting, and membranes were probed for AR, cPARP, and cleaved caspase 3. Membranes were stripped 
and re‐probed with β‐actin antibody to confirm equal protein loading. Iso A, isosilybin A; CI, caspase inhibitor. 
 
DISCUSSION 
 
PCA remains a leading cause of cancer‐related incidences and deaths among men in the United 
States [1]. To lower the rising PCA burden, more efforts are sought for developing selective and 
biological mechanism‐based therapies that are effective against PCA cells. In this regard, 
considerable attention has been focused on identifying naturally occurring nontoxic 
chemopreventive or chemotherapeutic phytochemicals with the aim of inhibiting, retarding, or 
reversing the carcinogenesis process leading to PCA [2-4]. In this context, the results from the 
present study are noteworthy as isosilybin A treatment inhibited cell survival signaling and 
activated intrinsic and extrinsic pathways of the apoptotic machinery in different PCA cells. 
 
DR5 belongs to the TNFR gene superfamily and is considered an attractive therapeutic target to 
induce apoptosis in a variety of cancers [17, 18, 36]. DR5 contains an extracellular ligand‐
binding domain and a homologous cytoplasmic death domain (DD) that mediate its interaction 
with DD‐containing adaptor proteins such as FADD or TNF‐associated DD (TRADD) [17, 18]. 
These adaptor molecules regulate the activation of downstream signaling molecules including 
caspase 8. The activated caspase 8 could activate caspase 3 either directly or via mitochondrial 
engagement through cleavage of BID and activation of caspase 9 [16-18]. In our study, isosilybin 
A treatment did not result in the cleavage of BID (data not shown); therefore, it could be 
presumed that the isosilybin A‐mediated activation of caspase 9 is independent of caspase 8 
activation. It has also been reported earlier that the cellular DNA damage could induce 
transcriptional upregulation of DR5 through p53 dependent and independent mechanisms [37]. 
In our previously published work, we have reported that isosilybin A treatment increases the 
cellular pool of total p53. Whether that is responsible for isosilybin A‐mediated increased levels 
of DR5 remains to be studied in future studies. 
 
Activated Akt is known to control crucial tumor‐associated cellular processes, including cell 
proliferation, cell‐cycle progression, tissue invasion, migration, and suppression of anoikis and 
apoptosis [15, 38, 39]. Several studies have also reported that inhibition of the PI3K/Akt 
pathway leads to sensitization of cancer cells to apoptosis [15, 38-40]. The antiapoptotic role of 
Akt is mediated through phosphorylation and inactivation of various apoptosis‐related proteins 
like caspase 9 and BAD [41]. In the present study, we observed a strong decrease in Akt 
phosphorylation by isosilybin A treatment, which could directly or indirectly contribute to the 
apoptosis induction in PCA cells. 
 
The transcription factor NF‐κB plays an important role in tumor growth, progression, and 
chemotherapy resistance through its ability to suppress cell death pathways [30, 31, 42]. 
Regulation by NF‐κB has been described for more than 150 genes including many antiapoptotic 
proteins such as Bcl2, Bcl‐xL, and various inhibitor of apoptosis proteins (IAPs) [43]. Webster 
and Perkins [44] reported that NF‐κB could abrogate p53‐mediated apoptosis by competing for 
nuclear co‐activators such as p300/CBP. Results from present study indicate that isosilybin A 
treatment decreases the nuclear levels of p50 and p65 in three PCA cell lines, which could result 
in a decreased expression of various antiapoptotic proteins. Therefore, isosilybin A‐mediated 
decreases in the nuclear level of NF‐κB members could directly potentiate the cellular apoptotic 
machinery. 
 
The abnormal modulation of the androgen‐AR signaling cascade plays a critical role in the 
growth and progression of human PCA [45, 46]. Androgen deprivation has been reported to 
induce apoptosis in PCA cells, which could be overcome by AR overexpression during 
progression towards hormone‐refractory stage [47-49], demonstrating the antiapoptotic and 
prosurvival role of AR in PCA cells. A study by Liao et al. [50] suggested a direct role of AR in 
apoptosis regulation in PCA cells. This study illustrated that the silencing of AR using small‐
interfering RNA leads to apoptotic death in PCA cells [50]. Furthermore, this study also 
demonstrated the involvement of AR in the regulation of Bcl‐xL expression, which is an 
important antiapoptotic member of the Bcl2 family [50]. Results from the present study showed 
an inhibitory effect of isosilybin A on AR signaling, which could result in decreased survival as 
well as activation of apoptotic machinery in PCA cells. Importantly, our results also showed that 
effect of isosilybin A on AR could be a primary event as a decrease in AR was evident much 
earlier relative to caspase activation and apoptosis induction. 
 
As mentioned earlier, the Akt–NF‐κB–AR signaling complex plays a critical role in the 
progression of PCA [15, 19-21]. Recent studies have shown a substantial degree of cross‐talk 
among these three molecules [12, 15, 19, 20, 51-53]. The role of Akt has been established in the 
activation of NF‐κB via phosphorylation through activation of inhibitor of kappa B kinase 
(IKK) [15]. Further, Akt has been reported to phosphorylate AR at specific sites leading to its 
activation or degradation depending upon the cellular physiological context or presence/absence 
of other signaling molecules [12, 19-21]. Similarly, the relationship between NF‐κB and AR 
remained controversial. NF‐κB binding sites have been reported in the promoter region of AR, 
and NF‐κB has been shown to play a role in AR activation under various conditions [52]. A role 
for NF‐κB has also been reported in the activation of PSA through direct binding to a 
transcriptional enhancer in the PSA gene [53]. Contrary to these results, Palvimo et 
al. [51] reported that the elevated expression of NF‐κB represses AR‐mediated transactivation. 
This complex interaction between these three molecules is suggestive of the fact that a 
simultaneous targeting of the Akt–NF‐κB–AR signaling axis is indispensable for an effective 
treatment of clinical PCA. Therefore, the results from present study are highly significant as 
isosilybin A strongly inhibits all the three members of the complex Akt–NF‐κB–AR signaling 
axis. 
 
In conclusion, the present study showed that isosilybin A could activate extrinsic and intrinsic 
pathways of apoptosis through targeting of the Akt–NF‐κB–AR axis. Since targeting apoptosis is 
a promising strategy for cancer treatment and management, isosilybin A could be an important 
addition to the arsenal of selective nontoxic drugs in our fight against cancer. 
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